• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited

    10/15/25 10:15:02 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CUPR alert in real time by email
    6-K 1 form6-k.htm 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of October 2025

     

    Commission File Number: 001-42288

     

    Cuprina Holdings (Cayman) Limited

    (Registrant’s Name)

     

    c/o Blk 1090 Lower Delta Road #06-08

    Singapore 169201

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒   Form 40-F ☐

     

     

     

     
     

     

    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

     

    Changes in Registrant’s Certifying Accountant

     

    Discontinuation of the Services from the Company’s Independent Registered Public Accounting Firm

     

    Cuprina Holdings (Cayman) Limited (the “Company”) is furnishing this current report on Form 6-K to report the dismissal of Kreit & Chiu CPA LLP (“K&C”) effective October 15, 2025. The dismissal of K&C has been considered and approved by the board of directors (the “Board”) of the Company.

     

    K&C’s reports on the Company’s financial statements for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles. Furthermore, during the Company’s two most recent fiscal years and through October 14, 2025, there have been no disagreements with K&C on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to K&C’s satisfaction, would have caused K&C to make reference to the subject matter of any such disagreements in connection with its reports on the Company’s financial statements for such periods.

     

    For the fiscal years ended December 31, 2024 and 2023 and through October 14, 2025, there were no “reportable events” as that term is described in Item 16F(a)(1)(v) of the Form 20-F.

     

    The Company provided K&C with a copy of the above disclosure and requested that K&C furnish the Company with a letter addressed to the U.S. Securities and Exchange Commission stating whether or not it agrees with the above statement. A copy of K&C’s letter is filed as Exhibit 16.1 to this Form 6-K.

     

    Appointment of New Independent Registered Public Accounting Firm

     

    The Company has appointed J&S Associate PLT (“J&S”) as successor auditor of the Company effective October 15, 2025 to audit the Company’s consolidated financial statements for the fiscal year ending December 31, 2025. The appointment of J&S has been approved by the Board and the audit committee.

     

    During the Company’s two most recent fiscal years and through October 14, 2025, neither the Company nor anyone acting on the Company’s behalf consulted J&S with respect to any of the matters or reportable events set forth in Item 16F(a)(2)(i) and (ii) of the Form 20-F.

     

    Exhibit Index

     

    Exhibit No.   Description
    99.1   Letter of Kreit & Chiu CPA LLP dated October 15, 2025.

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Cuprina Holdings (Cayman) Limited
         
      By: /s/ David Quek Yong Qi
      Name: David Quek Yong Qi
      Title: Chief Executive Officer and Director

     

    Date: October 15, 2025

     

     

    Get the next $CUPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CUPR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CUPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cuprina Holdings (Cayman) Limited Announces Financial Results for the Six Months Ended June 30, 2025, and Strategic Initiatives for 2026 Growth

    SINGAPORE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today  announced its financial results for the six months ended June 30, 2025. "Although our revenue decreased and our net loss increased compared with the same period last year, the first six months of 2025 allowed us to achieve significant advances in both diversifying our product and technology portfolio and expanding our geographic footprint," said Cuprina Chief Executive Officer, Mr. David Quek Yong Qi. Diversification

    12/9/25 8:30:00 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cuprina Holdings (Cayman) Limited Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

    SINGAPORE, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, and cosmeceuticals sectors, today announced it has received a letter of noncompliance from The Nasdaq Stock Market LLC ("Nasdaq"), dated November 26, 2025, notifying the Company that based on Cuprina's closing bid price for the last 30 consecutive business days, the Company no longer meets the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A), th

    11/28/25 8:30:00 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cuprina Signs MOU with Singapore Biowaste Solutions to Integrate Medical Waste Management Technologies

    SINGAPORE, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, and cosmeceuticals sectors, today said it has signed a Memorandum of Understanding (MOU) with Singapore Biowaste Solutions Pte Ltd (SBS), a treater and disposer of bio-medical waste, to explore the integration of Cuprina's medical waste recycling technology into SBS's existing waste management facility in Singapore. The collaboration aims to develop an integrated process that will further reduce reliance on incineration and landfilling, enhance recycling efficiency, unlock new

    10/27/25 8:40:00 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUPR
    SEC Filings

    View All

    SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited

    6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

    12/9/25 8:25:53 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited

    6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

    11/28/25 8:30:31 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited

    6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

    11/18/25 8:30:12 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUPR
    Leadership Updates

    Live Leadership Updates

    View All

    Cuprina Appoints Dr. Ronald Sherman, Leader in Maggot Debridement Therapy, as Medical and Scientific Director; Secures FDA-approved Medical Maggot License for U.S. Market

    SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("CUPR" or "the Company"), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that Dr. Ronald A. Sherman, a leading innovator in the use of medical maggots to treat chronic wounds, has agreed to join the Company as Medical and Scientific Director in September 2025. Cuprina also announced it has signed an agreement with Dr. Sherman licensing his 2004 FDA clearance to market Lucilia sericata Medical MaggotsTM, the first

    7/21/25 9:00:00 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care